polyerythritol monolaurate | 906328-28-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: polyerythritol monolaurate
• 英文别名: [(2S,3R)-2,3,4-trihydroxybutyl] dodecanoate
• CAS: 906328-28-7
• 化学式: C₁₆H₃₂O₅
• 分子量: 304.427
• InChiKey: DHMWAFVSSRVCPH-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  Erythritol 、 月桂酸甲酯 在 sodium carbonate 作用下， 生成 polyerythritol monolaurate
  参考文献：
  名称：

  Polyol polymers, meso-erythritol polymers and their aliphatic acid esters and aliphatic ethers

  摘要：

  提供具有更多羟基的多元醇聚合物，具有更多羟基的多元醇聚合物的脂肪酸酯，以及具有更多羟基的多元醇聚合物的脂肪醚。提供通过聚合含有中丙二醇的多元醇获得的聚合物，以及聚合物的脂肪酸酯和脂肪醚。

  公开号：

  US20030017132A1

文献信息

• NON-FLUORINATED URETHANE BASED COATINGS
  申请人：THE CHEMOURS COMPANY FC LLC

  公开号：US20160090508A1

  公开（公告）日：2016-03-31

  The present invention is an aqueous composition comprising at least one hydrophobic compound having at least one linkage of Formula I: —NHC(O)—X—  (I) wherein X is the residue of a cyclic or acyclic sugar alcohol which is substituted with at least one —R 1 ; —C(O)R 1 ; —(CH 2 CH 2 O) n (CH(CH 3 )CH 2 O) m R 2 ; —(CH 2 CH 2 O) n (CH(CH 3 )CH 2 O) m C(O)R 1 ; or mixtures thereof; where the cyclic or acyclic sugar alcohol is selected from a saccharide, reduced sugar, aminosaccharide, aldonic acid, or aldonic acid lactone; wherein each n is independently 0 to 20; each m is independently 0 to 20; m+n is greater than 0; each R 1 is independently a linear or branched alkyl group having 5 to 29 carbons optionally comprising at least 1 unsaturated bond; each R 2 is independently —H, a linear or branched alkyl group having 6 to 30 carbons optionally comprising at least 1 unsaturated bond, or mixtures thereof.

  本发明涉及一种水性组合物，其中至少包含一种具有至少一个式I连接的疏水化合物：—NHC（O）—X—（I），其中X是一个环状或非环状糖醇的残基，该糖醇被至少一个—R1；—C（O）R1；—（CH2 ）n（CH（CH3）CH2O）mR2；—（CH2 ）n（CH（ ） ）mC（O）R1；或其混合物所取代，所述环状或非环状糖醇从葡萄糖、还原糖、氨基葡萄糖、醛酸或醛酸内酯中选择；其中每个n独立地为0到20；每个m独立地为0到20；m+n大于0；每个R1独立地为具有5到29个碳原子的线性或支链烷基，可选地包含至少1个不饱和键；每个R2独立地为—H，具有6到30个碳原子的线性或支链烷基，可选地包含至少1个不饱和键，或其混合物。
• Non-fluorinated urethane based coatings
  申请人：THE CHEMOURS COMPANY FC LLC

  公开号：US10246608B2

  公开（公告）日：2019-04-02

  The present invention is an aqueous composition comprising at least one hydrophobic compound having at least one linkage of Formula I: —NHC(O)—X—  (I) wherein X is the residue of a cyclic or acyclic sugar alcohol which is substituted with at least one —R1; —C(O)R1; —(CH2CH2O)n(CH(CH3)CH2O)mR2; —(CH2CH2O)n(CH(CH3)CH2O)mC(O)R1; or mixtures thereof; where the cyclic or acyclic sugar alcohol is selected from a saccharide, reduced sugar, aminosaccharide, aldonic acid, or aldonic acid lactone; wherein each n is independently 0 to 20; each m is independently 0 to 20; m+n is greater than 0; each R1 is independently a linear or branched alkyl group having 5 to 29 carbons optionally comprising at least 1 unsaturated bond; each R2 is independently —H, a linear or branched alkyl group having 6 to 30 carbons optionally comprising at least 1 unsaturated bond, or mixtures thereof.

  本发明是一种水性组合物，包含至少一种具有至少一种式 I 连接的疏水化合物： -NHC(O)-X- (I) 其中 X 是被至少一个-R1；-C(O)R1；-(CH2 )n(CH(CH3)CH2O)mR2；-(CH2 )n(CH( ) )mC(O)R1 取代的环状或无环糖醇的残基；或其混合物；其中环状或无环糖醇选自糖、还原糖、氨基糖、醛酸或醛酸内酯；其中每个 n 独立地为 0 至 20；每个 m 独立地为 0 至 20；m+n 大于 0；每个 R1 独立地为具有 5 至 29 个碳原子、任选包含至少 1 个不饱和键的直链或支链烷基；每个 R2 独立地为-H、具有 6 至 30 个碳原子、任选包含至少 1 个不饱和键的直链或支链烷基，或其混合物。
• US4436649A
  申请人：——

  公开号：US4436649A

  公开（公告）日：1984-03-13
• [EN] PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE<br/>[FR] FORMULATIONS PHARMACEUTIQUES COMPRENANT DU 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPÉRAZIN-1-YL)-2-(1,3-DIMÉTHYL-1 HPYRAZOL-4-YL)-3 H-IMIDAZO[4,5-B]PYRIDINE
  申请人：ELLIPSES PHARMA LTD

  公开号：WO2021176214A1

  公开（公告）日：2021-09-10

  The present invention relates to formulations comprising a compound of Formula (1) (6-chloro-7-(4-(4- chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine) which is an inhibitor of Aurora kinase enzyme activity and FMS-like tyrosine kinase 3 (FLT3) activity, and a non-ionic surfactant. The present invention also relates to processes for the preparation of the formulations of the compound, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Aurora kinase and/or FLT3 activity is implicated.